Saturday, February 20, 2021 3:10:36 PM
You might be very right, but on the other hand a BP partner who took say a 20% to 30% position in the company would bring in a great deal of funding and establish a much higher trading range. While this partner would certainly be in the catbird seat when it came to buying out the company, it wouldn't be assured.
Personally I'm not pushing the idea of a buyout at all, I believe shareholders will be rewarded tremendously if we maintain independence, which can be done with a BP partner funding much of the work.
I agree with those who think a buyout under $30 billion wouldn't be acceptable, but long term I believe the company could reach a triple digit billion market cap is approval is gained for multiple solid cancers, and that's possible in under a decade.
I believe a partner recognizing the potential of the DCVax's could agree to purchase a percentage of the company based on the potential valuation now, i.e. if today they see $25 billion a fair price for the company, paying $2.5 billion for 10% would be reasonable. That should immediately bring the share price to somewhere near $20. I'm not saying it will happen, but investors would be well served if it did.
Gary
Personally I'm not pushing the idea of a buyout at all, I believe shareholders will be rewarded tremendously if we maintain independence, which can be done with a BP partner funding much of the work.
I agree with those who think a buyout under $30 billion wouldn't be acceptable, but long term I believe the company could reach a triple digit billion market cap is approval is gained for multiple solid cancers, and that's possible in under a decade.
I believe a partner recognizing the potential of the DCVax's could agree to purchase a percentage of the company based on the potential valuation now, i.e. if today they see $25 billion a fair price for the company, paying $2.5 billion for 10% would be reasonable. That should immediately bring the share price to somewhere near $20. I'm not saying it will happen, but investors would be well served if it did.
Gary
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
